FOXO4-DRI Price: $5.87 to $8.07 per mg, Same Vial

One product, one price, three defensible answers depending on which batch is in your hand.

The spread between best and worst case is roughly 37%. It runs in the buyer's favour on one batch and against them on the other, which is worth stating plainly rather than framing purely as a warning.

Neither certificate is defective. Purity and net content are separate measurements, and both batches tested above 99% pure. Quantity is what moved, and quantity is the measurement almost nobody in this market publishes.

There is only one vial size, so the per-milligram advantage that usually comes with a larger format does not exist here. Quantity is the only lever.

Those are reductions against the current price rather than the discounted price. Whether a quantity tier and the code combine is worth reading off the cart total rather than assuming, because the answer determines whether bulk is worth it at all.

Free carriage begins at $250, which a single discounted vial does not reach.

On most compounds, per-milligram cost is the honest comparison and the one this site pushes readers toward. Here it carries an assumption that does not hold.

The assumption is that the labelled mass is the delivered mass. For a product whose two published assays differ by 3.11 mg on a 10 mg label, that assumption is doing more work than the comparison can bear. A supplier quoting $6.70/mg is quoting the label. A supplier quoting nothing at all is not measuring.

The comparison that survives is documentation per dollar: does the supplier publish a batch-specific certificate from a named laboratory, run identity as well as purity, and state a measured content figure? That standard is portable across compounds and is the one applied in our NAD calculator notes, where quantities are large enough that fill variance is easier to see.

A cost page for an approved medicine would compare copay against cash price and weigh manufacturer savings programmes. None of that framework exists here.

FOXO4-DRI holds no marketing authorisation from the FDA, the EMA or the MHRA. No approved product means no formulary placement, no negotiated rate, no savings card and nothing for an insurer to reimburse. It has also never been administered in a registered human trial, so the evidence that normally precedes those arrangements does not exist either.

Research-supply pricing is therefore the only pricing there is, set by suppliers competing on cost and, occasionally, on documentation.